Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.61 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.52 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.52 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | LPL | P06858 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27989815 | 0.81 | CYP2A6 (0.74) | CYP17A1CYP11B1CYP11B2CYP2A6CYP2E1 | |
| SCHEMBL112601 | 0.80 | PRMT6 (0.63) | TAAR1CYP2A6CYP2E1CYP2B6LOXL2 | |
| SCHEMBL5877900 | 0.80 | CYP17A1 (0.50) | HRH3CYP17A1CYP11B1CYP11B2TAAR1 | |
| SCHEMBL8309627 | 0.78 | CYP17A1 (0.56) | CYP17A1CYP11B1CYP11B2CYP2A6CYP2E1 | |
| SCHEMBL7445908 | 0.78 | CYP17A1 (0.56) | CYP17A1CYP11B1CYP11B2CYP2A6CYP2E1 | |
| SCHEMBL5023933 | 0.78 | CYP17A1 (0.56) | CYP17A1CYP11B1CYP11B2CYP2A6CYP2E1 | |
| SCHEMBL5828167 | 0.78 | CYP17A1 (0.56) | CYP17A1CYP11B1CYP11B2CYP2A6CYP2E1 | |
| SCHEMBL8343615 | 0.78 | CYP17A1 (0.56) | CYP17A1CYP11B1CYP11B2CYP2A6CYP2E1 | |
| SCHEMBL4056073 | 0.78 | CYP17A1 (0.56) | CYP17A1CYP11B1CYP11B2CYP2A6CYP2E1 | |
| SCHEMBL2274647 | 0.78 | HRH3 (1.00) | HRH3TAAR1CYP2A6LOXL2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | disclosed |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| CN-107573386-A | Complex of iridium containing thieno [2,3 d] pyrimidine group and the application in electroluminescent device | 武汉大学 | 2018-01-12 | — | — | CN | disclosed |
| US-20160257673-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9259426-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-8809365-B2 | 1-substituted 2-azabicyclo [3.1.1] heptyl derivatives useful as nicotinic acetylcholine receptor modulators for treating neurologic disorders | UNIVERSITEIT GENT (BE) | 2014-08-19 | — | — | US | disclosed |
| US-8673929-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2406263-B1 | PYRAZOLO[1,5-A]-1,3,5-TRIAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CENTRE NAT RECH SCIENT (FR) | 2013-09-25 | — | — | EP | disclosed |
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| WO-2008003149-A2 | SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES , INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1813623-A1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-7109330-B2 | Purine inhibitors of cyclin dependent kinase 2 and IκB-α | CV THERAPEUTICS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1150982-B1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-alpha | CV THERAPEUTICS INC (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1021186-B1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha | CV THERAPEUTICS INC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | LUM ROBERT T (US) | 2005-04-14 | — | — | US | disclosed |
| US-6794390-B2 | TREATING CELL PROLIFERATIVE DISORDERS SUCH AS RHEUMATOID ARTHRITIS, LUPUS, TYPE I DIABETES, MULTIPLE SCLEROSIS, CANCER, RESTENOSIS, HOST GRAFT DISEASE, GOUT, AND POLYCYSTIC KIDNEY DISEASE. | CV THERAPEUTICS, INC. | 2004-09-21 | — | — | US | disclosed |
| US-6790958-B2 | ANTIPROLIFERATIVE AGENTS; FUNGICIDES | LUM ROBERT T (US) | 2004-09-14 | — | — | US | disclosed |
| CN-1353713-A | Purine inhibitors of cyclin dependent kinase 2 and IK B-alpha | CV THERAPEUTICS INC (US) | 2002-06-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | HRH3 168/4885CYP17A1 2387/4885CYP11B1 858/4885 |
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | IKBKB, NFKB1, CDK4 | HRH3 635/4885CYP17A1 3052/4885CYP11B1 2977/4885 |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR4A1 | HRH3 168/4885CYP17A1 2387/4885CYP11B1 858/4885 |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | NUDT1, SLC28A2, PNP | HRH3 504/4885CYP17A1 2505/4885CYP11B1 864/4885 |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR5A2 | HRH3 123/4885CYP17A1 2367/4885CYP11B1 835/4885 |
| US-20160257673-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR5A2 | HRH3 123/4885CYP17A1 2367/4885CYP11B1 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.